|
As reported by the field clinical specialist (fcs) the patient had a transfemoral transcatheter aortic valve replacement (tavr) with a 23mm sapein 3 ultra resilia valve and approximately 6 months and 27 days later the patient expired.The patient was admitted on 2 days prior to passing with acute on chronic heart failure with preserved ejection fraction complicated by acute respiratory failure and pleural effusions.The transthoracic echocardiogram (tte) performed one day before the patient expired showed severe prosthetic valve aortic stenosis, with an aortic valve mean gradient of 85mmhg and aortic valve area vti of 0.31 cm2.After discussions involving family and the patient's power of attorney (poa), code status was clarified as do not resuscitate/do not intubate.The patient was transitioned to comfort-focused care and ultimately patient expired.
|
|
A supplemental mdr is being submitted due to engineering evaluation findings.Sections g6, h2, h6: type of investigation, investigation findings, investigation conclusions and conclusions in this section have been updated.The event reported is anticipated in the risk management documentation for transcatheter heart valve procedures.A previous investigation into this type of event is captured in an edwards lifesciences technical summary and applies to this complaint.Additional assessment of the failure mode is not required at this time.The device was not returned for evaluation.Due to the unavailability of the complaint device, engineering was unable to perform any visual inspection, functional testing, or dimensional analysis.Per the technical summary, the instructions for use (ifu), training manuals and current risk mitigations have been reviewed.No inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.Through extensive complaint investigations, stenosis/increased gradient events for the s3, s3u, s3ur valves post-implantation have not been associated with device malfunctions or manufacturing nonconformances.Rather, the root cause for these events have historically been due to patient factors (atherosclerosis, thrombosis, endocarditis, rheumatic fever, pannus formation) and/or procedural factors (under-deployed valve, valve size selection, patient-prosthesis mismatch).The complaint for stenosis was confirmed based on provided medical record.It is possible that patient or procedural factors identified in the technical summary contributed to the complaint event.However, due to insufficient information, a definitive root cause cannot be determined.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.Since no edwards product defects or labeling deficiencies were identified, no corrective or preventative action is required.
|